HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In First For US OTC Market, Advil Line Extension Combines Ibuprofen And Acetaminophen

Executive Summary

CDER approval of Pfizer's NDA introduces a new formulation to the US OTC market. Labeling for was approved with the requirement of adding bullet points for an “Acetaminophen liver damage warning” and an “NSAID stomach bleeding warning” on all immediate containers.

You may also be interested in...



UK MHRA Approves Sale Of Reckitt’s Nuromol Outside Pharmacy

Reckitt's Nuromol is the first combination of paracetamol and ibuprofen approved for sale in the UK outside of pharmacy. The company has also been granted one year of exclusivity for the data used to secure the reclassification.

US Consumer Health 2020 News: ’60 Minutes’ Probiotic Dip Tops Switches, Monograph, Pandemic

Supplement industry’s bullseye on “60 Minutes” after its June segment critical of probiotic health benefits generated the most reads for a US consumer health and overall for HBW Insight articles in 2020. Articles about COVID-19 enforcement actions weren’t as widely read as coverage of FDA’s reorganization in its OTC drug offices and its approvals of additional ingredients to be available OTC.

GSK Rides E-Commerce Wave In Choppy COVID Waters

GSK saw investments in e-commerce paying off in 2020 as the firm was able to meet increased demand for consumer health products during the pandemic while many shoppers remained indoors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS149751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel